Bizarre Patents
Neuroimaging as a Marketing Tool
Neuroimaging as a means for validating whether a stimulus such as advertisement, communication, or product evokes a certain mental response such as emotion, preference, or memory, or to predict the consequences of the stimulus on later behavior such as consumption or purchasing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7414154 | Polyamine compounds and compositions for use in conjunction with cancer therapy The invention provides novel polyamine compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemoth... | 08/19/2008 |
| 7314959 | Amino thiol compounds and compositions for use in conjunction with cancer therapy The invention provides novel polyamine and amino thiol compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-ef... | 01/01/2008 |
| 7279502 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions... | 10/09/2007 |
| 7201854 | Active compound combinations for protecting animal hides and leather The present application relates to the use of active compound combinations containing phenolic active compounds and fungicidal active compounds for preserving animal hides and leather. ... | 04/10/2007 |
| 7198946 | Screening for agents effective in decreasing abnormal macrophages associated with amyotrophic lateral sclerosis The invention provides methods of monitoring amyotrophic lateral sclerosis (ALS) disease development or progression and monitoring an ALS therapy by determining the level of HLA-DR expression by CD14+ monocytes and/or the percentage of CD16+ cells in the population ... | 04/03/2007 |
| 7045550 | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy Polyamine effectors are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more polyamine effectors formulated fo... | 05/16/2006 |
| 6908948 | DNA-cleaving antitumor agents A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediynes, aza-enyne allenes, or an aza-diallenes. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acids. In ad... | 06/21/2005 |
| 6852341 | Azide method and composition for controlling deleterious organisms and for stimulating beneficial organisms Disclosed is both a method and composition for controlling deleterious organisms, such as insects, nematodes and weeds while maintaining beneficial soil organisms, by applying a compound comprised of a liquid medium and comprising an azide and an amino acid polymer.... | 02/08/2005 |
| 6830754 | Amphipatic lipid dispersion Described in the present invention are a dispersion which comprises, as a dispersoid, (a) 5 to 40 wt. % of an amphipatic lipid containing, in the molecule thereof, at least one hydroxy and amide group, and (b) 2 to 55 wt. % of a surfactant in an aqueous medium; a wa... | 12/14/2004 |
| 6809120 | Composition containing propargylamine for enhancing cancer therapy Antineoplastic drug modulators are described. The specific modulators referred to are propargylamines which can enhance the cytotoxic effects of antineoplastic drugs on cancer cells while protecting normal cells from damage. The propargylamine modulators can be used... | 10/26/2004 |
| 6794545 | Conformationally restricted polyamine analogs as disease therapies Novel conformationally restricted polyamine analogs are provided, as well as compositions comprising these novel polyamine analogs. Methods of using the novel polyamine analogs in treatment of diseases such as cancer are also provided. Also provided is a method of d... | 09/21/2004 |
| 6727288 | Method for treating bone fracture The present invention relates to a method for treating or preventing bone fracture, which comprises administering an effective amount of calcium L-threonate to a subject in need of such prevention or treatment. It had been found from experiments that calcium L-threo... | 04/27/2004 |
| 6713513 | Method for treating cartilage related diseases The present invention relates to a method for preventing or treating of cartilage related diseases, such as osteoarthritis, rheumatoid arthritis, articular cartilage damage, multiple chondritis, osteochondrosis, etc., which comprises administering an effective amoun... | 03/30/2004 |
| 6686345 | DNA-cleaving antitumor agents A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediyne, aza-enyne allene, or an aza-diallene. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acid... | 02/03/2004 |
| 6649587 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as c... | 11/18/2003 |
| 6605641 | 20-HETE antagonists and agonists 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid, 20-hydr... | 08/12/2003 |
| 6599941 | Insecticide and insect repellant compositions A non-toxic, environmentally safe and easily employable insecticide and insect repellent is achieved by providing an aqueous composition incorporating ethanolamine based compounds, either independently or in combination with the ethanolamine based compoun... | 07/29/2003 |
| 6596769 | 20-Hete antagonists and agonists 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hy... | 07/22/2003 |
| 6582683 | Dermal barrier composition Disclosed is a dermal barrier composition which contains a hydrophilic polymer emulsion and a hydrophobic polymer emulsion. The dermal barrier composition is moisture activated, and remains inert until the hydrophobic and hydrophilic polymer emulsions con... | 06/24/2003 |
| 6482833 | Immunotherapeutic anti-cancer pharmaceutical compositions There is disclosed a class of pharmaceutical compositions useful for the treatment of cancer, particularly solid tumors, and having a mechanism of action as spermine antagonists. The present pharmaceutical compositions are able to inhibit the inhibitory e... | 11/19/2002 |
| 6395781 | 20-HETE antagonists and agonists 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hy... | 05/28/2002 |
| 6297284 | DNA-cleaving antitumor agents A chemical composition and method of use of the composition is described. The chemical composition includes an aza-enediyne, aza-enyne allene, or an aza-diallene. These compound are preferably non-hydrolyzable, cationic compounds that bind to nucleic acid... | 10/02/2001 |
| 6251950 | Aliphatic propargylamines as cellular rescue agents The present invention relates to the use of a group of propargylamines of the general formula (I) ##STR1## wherein R1 is hydrogen or CH3 and R2 is (CH2)n CH3 and n is an integer from 0 to 1... | 06/26/2001 |
| 6248356 | Immunotherapeutic anti-cancer pharmaceutical compositions There is disclosed a class of pharmaceutical compositions useful for the treatment of cancer, particularly solid tumors, and having a mechanism of action as spermine antagonists. The present pharmaceutical compositions are able to inhibit the inhibitory e... | 06/19/2001 |
| 6153648 | Iodopropargylamine compounds, and industrial antimicrobial and antifungal agents, algicides, and antifouling agents containing the same Iodopropargylamine compound of the general formula (1): ##STR1## wherein R1 and R2 each independently represent a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or R1 and R2 combine with each o... | 11/28/2000 |
| 6103768 | Fatty acid based compositions and methods for the control of plant infections and pests The invention described here concerns the unique utility of fatty acids and their derivatives to eradicate existing fungal and bacterial infections in plants. Also, described herein are combination treatments whereby fatty acids are used to enhance or aug... | 08/15/2000 |
| 6077872 | Use of calcium L-threonate in preventing, inhibiting and curing osteoporosis and rickets The present invention relates to the use of calcium L-threonate, namely, to a method for preventing, inhibiting and curing osteoporosis and rickets using calcium L-threonate.... | 06/20/2000 |
| 6060454 | Compositions, apparatus and methods for facilitating surgical procedures Methods are provided for conducting surgical procedures in a patient wherein, during the surgical procedure, autonomous ventricular electrical conductivity and escape beats are reversibly and transiently suppressed to facilitate the surgical procedure. Al... | 05/09/2000 |
| 6028114 | Use of aminothiolester derivatives in pharmaceutics Use of at least one aminothiol ester derivative for the preparation of a pharmaceutical composition intended to increase the inhibition of a character resistant to the induction of apoptosis of transformed cells, this character being due to the bc12 gene ... | 02/22/2000 |
| 6004958 | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free ... | 12/21/1999 |
| 5859017 | Method for inhibiting mast cell and basophil activation In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and di... | 01/12/1999 |
| 5824693 | Method for treatment for pulmonary disease The present invention provides a method for treating pulmonary disease. More specifically, the present invention provides a method for treating diseases such as adult respiratory distress syndrome which result in oxidative stress that damages the cells of... | 10/20/1998 |
| 5760091 | Preventive agents against adhesion of marine organisms and methods of preventing such adhesion of marine organisms A preventive agent against adhesion of a marine organism comprising: at least one amine compound represented by the following formula (I): ##STR1## , wherein R is a C8-22 saturated or unsaturated aliphatic hydrocarbon group, R1 ... | 06/02/1998 |
| 5696128 | Method of regulating immune function Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by... | 12/09/1997 |
| 5681859 | Insecticide and insect repellant compositions A non-toxic, environmentally safe and easily employable insecticide and insect repellant is achieved by providing an aqueous composition incorporating ethanolamine based compounds, either independently or in combination with the ethanolamine based compoun... | 10/28/1997 |
| 5653973 | Lepidoptera bait Baits useful for controlling lepidoptera populations is made with (a) a diet component for lepidoptera; (b) a toxicant; (c) a chemiluminescent, visual attractant and (d) an encapsulating agent that will allow moisture to permeate and form an external cond... | 08/05/1997 |
| 5622995 | Methods for control and mitigation of molluscs A method is provided for controlling the proliferation of molluscs in target habitat by applying to the habitat a compound or mixture of compounds which are amines, ethoxylated amines, quaternary amines, ethoxylated quaternary amines and cyclic amines.... | 04/22/1997 |
| 5599847 | Antifungal compounds Compounds having the formula (I) below: (R1 R2 N)CH2 --CH.dbd.CH--CH2 (NR3 R4)(I) wherein R1, R2, R3 and R4, which may be the same or different represent h... | 02/04/1997 |
| 5587366 | Compositions useful in prophylaxis and therapy of endotoxin related conditions Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering phospholipid containing compositions to the subject. The compositions are protein and peptide free, and may contain triglycerides, or other polar or... | 12/24/1996 |
| 5587367 | Pharmaceutical or cosmetic composition containing a combination of a retinoid and a sterol A pharmaceutical or cosmetic composition is disclosed comprising in combination a retinoid and a sterol capable of inhibiting the biosynthesis of cholesterol resulting in a synergistic effect in the treatment of disorders of epidermic keratinization, prol... | 12/24/1996 |
